Improving safety of new diabetes medications for patients with diabetes and kidney disease
Optimizing the Safety of the Newer Diabetes Medications in Patients with Diabetes and Kidney Disease
This study is looking at how safe newer diabetes medications are for people who have both diabetes and kidney disease, especially older adults, so that doctors can confidently prescribe them to more patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11077255 on NIH RePORTER |
What this research studies
This research investigates the safety of newer diabetes medications, specifically sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA), in patients who have both diabetes and kidney disease. The study aims to address the lack of safety data for these medications in real-world settings, particularly among older patients with multiple health issues. By utilizing large national healthcare databases, the research will analyze the effects of these medications on a diverse group of patients, focusing on minimizing adverse events and drug interactions. The goal is to create a framework that ensures these medications can be safely prescribed to a broader range of patients with kidney disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with diabetes who also have kidney disease, particularly those who are older and may be taking multiple medications.
Not a fit: Patients without diabetes or kidney disease, or those who are not on any medications, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer prescribing practices for diabetes medications in patients with kidney disease, ultimately improving their health outcomes.
How similar studies have performed: Previous research has shown promising results in the safety and efficacy of similar diabetes medications, but this study aims to fill critical gaps in safety data for high-risk populations.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Paik, Julie — Brigham and Women's Hospital
- Study coordinator: Paik, Julie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.